Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $62.00

Olema Pharmaceuticals (NASDAQ:OLMA) had its price objective lifted by Citigroup from $60.00 to $62.00 in a report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also recently issued reports on OLMA. Guggenheim reduced their price objective on shares of Olema Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday. TD Cowen restated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright reduced their price target on shares of Olema Pharmaceuticals from $45.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $44.40.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $14.96 on Tuesday. The stock has a 50-day moving average price of $23.35 and a 200 day moving average price of $18.67. The stock has a market capitalization of $1.03 billion, a P/E ratio of -8.04 and a beta of 1.92. Olema Pharmaceuticals has a 12-month low of $2.86 and a 12-month high of $36.26. The company has a current ratio of 9.95, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. Equities research analysts forecast that Olema Pharmaceuticals will post -2.33 EPS for the current fiscal year.

Insider Activity

In related news, insider Naseem Zojwalla sold 100,000 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $28.04, for a total transaction of $2,804,000.00. Following the sale, the insider owned 53,997 shares of the company’s stock, valued at $1,514,075.88. This represents a 64.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Cyrus Harmon sold 10,000 shares of the stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $26.88, for a total transaction of $268,800.00. Following the transaction, the director owned 727,770 shares of the company’s stock, valued at $19,562,457.60. This trade represents a 1.36% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 419,701 shares of company stock worth $11,603,868. 16.36% of the stock is owned by corporate insiders.

Institutional Trading of Olema Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Bain Capital Life Sciences Investors LLC raised its position in shares of Olema Pharmaceuticals by 24.3% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after buying an additional 1,664,687 shares in the last quarter. Paradigm Biocapital Advisors LP grew its position in Olema Pharmaceuticals by 11.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock worth $188,604,000 after acquiring an additional 750,000 shares in the last quarter. Janus Henderson Group PLC grew its position in Olema Pharmaceuticals by 87.1% in the fourth quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company’s stock worth $167,901,000 after acquiring an additional 3,124,345 shares in the last quarter. Vanguard Group Inc. increased its stake in Olema Pharmaceuticals by 11.4% during the fourth quarter. Vanguard Group Inc. now owns 3,561,355 shares of the company’s stock worth $89,034,000 after acquiring an additional 364,035 shares during the last quarter. Finally, Deep Track Capital LP increased its stake in Olema Pharmaceuticals by 0.8% during the third quarter. Deep Track Capital LP now owns 3,470,172 shares of the company’s stock worth $33,973,000 after acquiring an additional 27,339 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Key Olema Pharmaceuticals News

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Jefferies initiated coverage with a “Buy” and $40 price target (large upside vs. current levels), giving fresh institutional endorsement that can attract buyers. Jefferies Initiates Coverage – Benzinga
• Positive Sentiment: JPMorgan raised its price target to $58 and kept an “Overweight” stance — a high-profile upward revision that can drive momentum and re-rate expectations. JPMorgan Raises Price Target – Benzinga
• Positive Sentiment: HC Wainwright lifted EPS estimates across 2026–2030 and reiterated a “Buy” with a $38 target, signaling analyst confidence in improving fundamentals over the medium term. HC Wainwright Estimate Raises – MarketBeat
• Positive Sentiment: Olema reported better‑than‑expected quarterly results this week, which, along with raised analyst outlooks, is a near‑term bullish catalyst supporting the stock. Earnings Beat Drives Stock – AmericanBankingNews
• Positive Sentiment: Upcoming/preclinical data (palazestrant and OP‑3136) to be presented at AACR and a large reported $68.7M investor bet on a 2027 breast‑cancer launch are potential medium‑term catalysts for upside if data or investor interest validates the story. AACR Presentation – BusinessInsider Large Bet Report – The Globe and Mail
• Neutral Sentiment: Zacks notes the stock has been heavily sold (down ~33% over 4 weeks) and is technically oversold; that increases the chance of a short‑term bounce but also underscores elevated downside risk if catalysts disappoint. Oversold / Technical Note – Zacks
• Negative Sentiment: Guggenheim published a pessimistic forecast and an analyst downgrade hit headlines, pressuring the stock intraday — a reminder that not all desks are aligned with the recent bullish notes. Guggenheim Pessimistic Forecast – AmericanBankingNews
• Negative Sentiment: AmericanBankingNews reported an analyst downgrade that coincided with a notable intra‑day pullback, illustrating how mixed analyst views are fueling volatility. Analyst Downgrade / Price Reaction – AmericanBankingNews
• Negative Sentiment: Goldman Sachs trimmed its price target from $38 to $27 (while keeping a “Buy”), which reduces the consensus upside and may cap near‑term rallies until data or execution de‑risk the story. Goldman Lowers Target – Benzinga

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.